BRCA2 and prostate cancer: BRCA2 reversion mutations are associated with the resistance of inhibitors of the DNA repair protein poly (ADP)-ribose polymerase (PARPi), such as olaparib and talazoparib in prostate cancer patients.[116] Evaluation of the plasma androgen receptor (AR) gene status (including AR amplification, multiple AR mutations, etc.[117]) identifies castration-resistant prostate cancer (CRPC) patients with a worse outcome and resistance to conventional prostate cancer drugs such as enzalutamide and abiraterone [118, 119].